

Occupational interstitial lung diseases

■ Paolo Spagnolo¹ , Christopher J. Ryerson², Sabina Guler³, Johanna Feary^{4,5}, Andrew Churg⁶, Andrew P. Fontenot^{7,8}, Sara Piciocchi⁹, Zarir Udwadia¹⁰, Tamera J. Corte^{11,12}, Wim A. Wuyts¹³, Kerri A. Johannson^{14,15} & Vincent Cottin^{16,17}

From the ¹Respiratory, Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padova, Italy; ²Department of Medicine, St. Paul's Hospital, University of British Columbia and Centre for Heart Lung Innovation, Vancouver, Canada; ³Department of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland; ⁴Department of Occupational and Environmental Medicine, Royal Brompton Hospital, London, UK; ⁵National Heart and Lung Institute, Imperial College London, London, UK; ⁶Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada; ⁷Department of Medicine, University of Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA; ⁸Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus Aurora, Aurora, Colorado, USA; ⁹Department of Radiology, G.B. Morgagni Hospital/University of Bologna, Forlì, Italy; ¹⁰Hinduja Hospital and Research Center, Breach Candy Hospital, Mumbai, Maharashtra, India; ¹¹NHMR Centre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia; ¹²Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; ¹³Unit for Interstitial Lung Diseases, University of Leuven, Leuven, Belgium; ¹⁴Department of Medicine, University of Calgary, Calgary, Alberta, Canada; ¹⁵Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; ¹⁶Department of Respiratory Medicine, National Reference Coordinating Centre for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Lyon, France; and ¹⁷Université de Lyon, Université Claude Bernard Lyon 1, UMR754, IVP, Lyon, France

Abstract. Spagnolo P, Ryerson CJ, Guler S, Feary J, Churg A, Fontenot AP, et al. Occupational interstitial lung diseases. *J Intern Med.* 2023;**294**:798–815.

Millions of workers are exposed to substances known to cause occupational interstitial lung diseases (ILDs), particularly in developing countries. However, the burden of the disease is likely to be underestimated due to under-recognition, under-reporting or both. The diagnosis of occupational ILD requires a high level of suspicion and a thorough occupational history, as occupational and non-occupational ILDs may be clinically, functionally and radiologically indistinguishable, leading to delayed diagnosis and inappropriate management. A potential occupational aetiology should always be considered in the differential diagnosis of ILD,

as removal from the workplace exposure, with or without treatment, is a key therapeutic intervention and may lead to significant improvement. In this article, we provide an overview of the 'traditional' inorganic dust-related ILDs but also address idiopathic pulmonary fibrosis and the immunologically mediated chronic beryllium disease, sarcoidosis and hypersensitivity pneumonitis, with emphasis on the importance of surveillance and prevention for reducing the burden of these conditions. To this end, health-care professionals should be specifically trained about the importance of occupational exposures as a potential cause of ILD.

Keywords: asbestosis, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, interstitial lung disease, occupational exposure, pneumoconiosis, silicosis

Introduction

Interstitial lung disease (ILD) is a large and highly heterogeneous group of conditions characterized by various degrees of inflammation and fibrosis of the lung parenchyma [1]. Epidemiological studies report that occupational ILDs, defined as potentially reversible diseases that result from occupational exposure to dust, fumes, smoke and biological agents, account for 10%–20% of all ILD cases [2]. Common examples of occupational ILDs include the pneumoconioses caused by exposure

to crystalline silica (silicosis), asbestos (asbestosis) and coal dust (coal worker's pneumoconiosis; CWP) [3], although the list of occupational exposures that may cause ILD continues to grow, emphasizing the need for ongoing vigilance and effective preventive measures.

Although millions of workers are exposed to substances known to cause occupational ILD, the disease burden is likely underappreciated due to under-recognition, under-reporting and difficulties in attributing causation, particularly for exposures

that are only rarely associated with ILD. In addition, assigning a specific occupational cause of ILD may be limited to cases awarded compensation that typically requires fulfilment of strict and specific legal and medical criteria. Varied latency periods contribute to an underestimation of the true disease prevalence and delayed or improper patient management.

The purpose of this article is to review the clinical approach to occupational ILDs and discuss possible avenues for early recognition and prevention. While focusing on the 'traditional' inorganic dust-related diseases, we also address idiopathic pulmonary fibrosis (IPF), the immunologically mediated chronic beryllium disease (CBD), sarcoidosis and hypersensitivity pneumonitis (HP) as well as selected conditions secondary to non-conventional or recently described exposures. ILDs that occur secondary to exposures in non-occupational settings are not included in the present article.

Epidemiology and defining features

The available epidemiological data on occupational ILDs are limited and frequently biased due to lack of standardized diagnostic criteria, limitations of available data sources (e.g. death certificates), and wide variation of regional practices in surveillance of exposed individuals and compensation rules (Table 1) [16]. The long latency period for some causative agents and potential confounding exposures (e.g. smoking) can challenge further causal assumptions. Some exposures (e.g. asbestos) may not be limited to the workplace, and disease can occur through other means [17]. Overall, the true incidence of occupational ILDs is likely underestimated particularly in low- and middle-income countries where reporting systems may be poor, control of workplace exposure less likely to be rigorous, and claims for recognition as work-related disease infrequent. The incidence and prevalence of occupational ILD ranged from 1.6% of all ILDs in an Australian and New Zealand registry to 10.4% based on a county chart review in New Mexico, with this large variability likely driven by variable local exposures [4, 18].

Pneumoconioses

Asbestos, silica and coal are the most common causative dusts inducing pneumoconiosis, whereas diseases caused by beryllium and hard metals are much less common. The Global Burden of Disease study identified more than 60,000

incident cases of pneumoconiosis in 2017; 39% of those were silicosis, 25% CWP and 16% asbestosis [10]. Pneumoconioses, though initially described in countries with a high sociodemographic index (SDI), are now seen mostly in developing countries and low SDI regions. In India, over 3 million workers are exposed to silica dust, with 8.5 million more working in construction [19, 20]. Another study from India found that the prevalence of radiological silicosis and progressive massive fibrosis (PMF) was 52% and 7.5%, respectively, among the 529 sandstone mineworkers screened [15]. In a Turkish study, 153 young denim sandblasters reported frequent symptoms, including dyspnea (52%), chest pain (46%) and chronic cough (19%). Based on chest X-rays, 77 (53%) were diagnosed with silicosis, with those diagnosed having a longer exposure duration and lower lung volumes compared to their counterparts [14]. The incidence of CWP has been declining in many regions of the world but is still increasing in some African regions, South-east Asia and Oceania [10]. Similarly, cases of rapidly progressive CWP continue to occur among coal miners [21]. In the long term, the incidence of asbestosis is also anticipated to decrease in countries where asbestos is no longer used for construction and manufacturing. However, due to the long latency period between exposure and disease, most regions will continue to report a large number of new cases before a drop in incidence can be expected [10].

Over the last two decades, reports from various countries around the world have suggested a concerning increase in silicosis caused by manufacturing and processing of artificial stone, which is largely used for the production of kitchen or bathroom countertops [22]. Artificial stone is composed of more than 90% quartz combined with polymer resins and pigments, which are then heat cured. Cutting of artificial stone produces particularly high levels of respirable crystalline silica dusts. Compared to silicosis developed in traditional silica exposure settings, this form of disease affects younger workers following shorter latency periods – due to either the higher intensity of exposure or increased toxicity of the dust, or both – and rapid progression to advanced lung disease [23–25]. In a recent study from the Bay of Cádiz (southern Spain), one third of patients with artificial stone silicosis progressed from simple silicosis to PMF after a mean of only 4 years of follow-up and despite being removed from continued exposure [26]. The true incidence and prevalence of this new

Table 1. Selected studies reporting the prevalence or incidence of occupational interstitial lung diseases (ILDs).

Study (first author, publication year)	Disease	Time frame	Region	Incidence (/100,000/year)
Population based studies				
Coultas, 1994 [4]	Occupational and environmental ILD	1988–1990	New Mexico, United States	I: Men: 6.2 Women: 0.8 P: Men: 20.6/100,000 Women: 0.6/100,000
McDonald, 2005 [5]	Pneumoconiosis	1992–2001	United Kingdom	I: 0.6–1
Barber, 2017 [6]	Occupational HP	1996–2015	United Kingdom	I: 0.14
Fenclová, 2009 [7]	Occupational HP	1992–2005	Czech Republic	I: 0–0.2
Death certificates				
Rosenman, 2003 [8]	Silicosis	1987–1996	Michigan state	I: 3600–7300/year in the United States
Carder, 2017 [9]	All pneumoconiosis	1996–2014	United Kingdom	I: 1.9
Carder, 2017[9]	Asbestosis	1996–2014	United Kingdom	I: 1.3
Global burden of disease analyses, ASIR/100,000/year				
Shi, 2020 [10]	Pneumoconiosis	2017		Overall 0.75 Men 1.45 Women 0.15
	Silicosis			I: 0.3
	Asbestosis			I: 0.12
	CWP			I: 0.19
	Pneumoconiosis		East Asia	I: 1.66
			Oceania	I: 1.45
			North America	I: 0.62
			Western Europe	I: 0.14
Li, 2022 [11]		2019	China	I: 6.7
Wang, 2021 [12]	CWP	2019	Global	I: 0.09
Proportion of silicosis among screened workforce				
Tjoe, 2003 [13]	Quartz dust exposed	1998	The Netherlands	P: 10.2%
Akgun, 2008 [14]	Denim sand blasters	1991–2006	Turkey	P: 53%
Nandi, 2021 [15]	Sandstone mine workers	NA	India	P: 52%

Abbreviations: ASIR, age-standardized incidence rate; CWP, coal worker's pneumoconiosis; HP, hypersensitivity pneumonitis; I, incidence; ILD, interstitial lung disease; P, prevalence.

form of silicosis remain unknown but are likely to continue to rise if practices are not changed. In this regard, ventilation systems and wet blade cutting methods are effective measures to reduce dust generation when working on artificial stone [27]. CWP (or 'coal pneumoconiosis') is caused by long-term (typically over ≥ 20 years) inhalation of dust from

high-carbon coal (anthracite and bituminous) and rarely graphite. Many cases will arise from co-exposures and radiologically have features of other diseases (e.g. silicosis in coal miners) [30]. Although pure coal pneumoconiosis is increasingly uncommon, severe and rapidly progressive cases of the disease continue to occur. Notably, affected

miners are significantly younger than other miners with CWP, implicating recent mining conditions [21].

An estimated 21,500 people died from pneumoconiosis in 2016 [28], and over 12,900 deaths were due to silicosis in 2019 [29]. With its large workforce, China is particularly impacted by pneumoconiosis, accounting for 44% of deaths globally [1]. Reassuringly, there seems to be an overall drop in mortality rates, although stagnant and increasing mortality rates are still reported in women and in low- and middle-income countries [29].

Chronic beryllium disease

Beryllium is utilized in the aerospace, ceramics, electronics and defence industries, and CBD occurs in 2%–16% of exposed workers [31, 32]. Exposure to beryllium remains a major public health concern, with an estimated 800,000 individuals currently at risk for developing beryllium sensitization (BeS) or CBD [31, 33]. In addition to workers directly exposed to beryllium, many more are likely to be exposed indirectly [34]. The disease is characterized by an accumulation in the lung of activated CD4+ T cells that respond to beryllium as an 'antigen' in an MHC class II-dependent manner [35–37]. Genetic susceptibility to CBD is strongly linked to *HLA-DPB1* alleles possessing a glutamic acid at the 69th position of the β -chain (β Glu69) [38, 39].

Cobalt-induced hard metal disease

Other metals, including aluminium, cobalt, titanium and zirconium, are associated with granulomatous lung disease. Cobalt-induced hard metal disease (also referred to as giant cell interstitial pneumonitis) has a strong association with β Glu69-containing HLA-DP alleles, similar to CBD [40]. The latency period between exposure and clinically overt disease ranges from months to years, with the development of cough and dyspnea heralding the onset of ILD.

Hypersensitivity pneumonitis

Occupational HP is estimated to account for one fifth of all HP cases [2]. The epidemiology of the disease has been investigated most frequently in farmers, with varying incidence being observed depending on agricultural practices and climate conditions. A high prevalence has been reported in mountain areas and countries with a cold and

humid climate [41, 42]. However, with the industrialization of many farming practices and application of preventive measures, the incidence may be falling [43]. Modern occupational HP is the most frequently reported in industrial environments, where solvents, chemicals and metalworking fluids are the main inciting agents [44]. Occupational HP may also occur in workplace outbreaks where multiple workers are affected [45, 46]. For instance, industrial machine-manufacturing workers may be exposed to metalworking fluids, which are heavily colonized by bacteria, such as *Pseudomonas pseudoalcaligenes* and *Curtobacterium*, although the metalworking fluid bacterial microbiome is likely to be far more complex [47]. The annual incidence of occupational HP in the United Kingdom is estimated at 1–2 cases per million, with metalworking fluids, farming and chemicals being the most frequent causative exposures [6]. Earlier reports from the Czech Republic showed similarly low incidences [7]. A US-based study reported the 1-year HP prevalence ranging from 1.67 to 2.71 per 100,000 persons, with a 1-year cumulative incidence of 1.28–1.94 per 100,000 among an insured population between 2004 and 2013 [48]. When occupational HP is suspected, industrial hygiene assessment or consultation with occupational respiratory specialists should be sought, given the frequent under-recognition of occupational HP by non-occupational specialists [49].

Sarcoidosis

Sarcoidosis is a systemic disorder characterized by the presence of granulomatous inflammation in affected organs. Disease pathogenesis remains poorly understood but is likely to involve a complex interplay between a triggering antigen (or, most likely, antigens) and the host genetic background leading to an exuberant immune response [50]. Although commonly referred to as a disease of 'unknown cause', epidemiological studies have revealed significant associations between multiple occupational exposures and increased risk for sarcoidosis [51, 52]. Using data from seven studies, Blanc et al. estimated that the contribution of occupational exposures to the burden of sarcoidosis was 30% (95% CI, 17–45) [2]. The a case control etiologic study of sarcoidosis study that recruited 706 patients newly diagnosed with sarcoidosis and 706 age-, race- and sex-matched controls found positive associations between sarcoidosis and agricultural employment (odds ratio [OR] 1.46), exposures to insecticides at work (OR 1.52) and work

environments with mould/mildew (OR 1.61) [53]. Further analysis of the same dataset revealed that workers for suppliers of building materials, hardware and gardening materials were also at higher risk of sarcoidosis [54]. In addition, firefighters exposed to World Trade Center 'dust' from construction and furnishing materials were found to be at significantly increased risk of developing sarcoidosis within the first 4 years after exposure [55], although it is difficult to identify the causative compound/s due to heterogeneity of the exposure. More recently, Beijer et al. found immunoreactivity to silica and metals (i.e. aluminium, zirconium and beryllium) in 21.2% of patients with sarcoidosis and 0% of controls, further supporting the hypothesis that these antigens may be pathogenetic in a significant minority of sarcoidosis patients [56].

IPF and other ILD subtypes

Occupational exposures are risk factors for several fibrotic ILDs, including those considered idiopathic such as IPF and other idiopathic interstitial pneumonias [57]. Indeed, although these entities are by definition of unknown aetiology, established mechanisms of lung injury support the hypothesis that inhaled exposures might contribute to disease pathogenesis and progression. However, while inferring causality in patients who develop an acute disease immediately after a high-intensity exposure is usually straightforward, determining the likelihood that any given exposure is causative is difficult when chronic low-level exposures occur over many months to years or if multiple exposures co-occur, particularly in the absence of a histological confirmation of the diagnosis. In such cases, the best approach remains suspecting the possibility of an exposure-related ILD and taking a thorough exposure history (e.g. exposure to agents known to cause ILD, cluster of disease in co-workers or age younger than expected).

Over the last two decades, several case-control studies have investigated the association between occupational exposures and IPF. In the largest meta-analysis to date, pooled findings from 11 cohort and case-control studies reported the following population attributable fractions: silica 3%, wood dusts 4%, metal dusts or fumes 8% and vapours, gases, dusts and fumes 26%, indicating that a quarter of IPF cases are attributable to occupational exposures [2]. A recent Australian study used a population-based control group to estimate the risk of IPF diagnosis by occupational

exposures [58]. Respirable (smaller than 10 μm) dust (OR 1.38) and asbestos (OR 1.57) were independently associated with increased risk of IPF. Similarly, a case-control study in Italy found that people with self-reported history of exposure to metal dust, metal fumes or organic dust were at higher risk of developing IPF, with longer exposure time conferring an increased risk of disease [59]. More recently, Park et al. performed a systematic review and meta-analysis of eight case-control studies including 3502 patients [57]. They confirmed that exposure to metal (OR 1.83) and wood dust (OR 1.62), pesticide (OR 2.07) and history of farming or agriculture work (OR 1.88) increased the risk of IPF.

For ILDs overall, registry-based studies show that inhaled exposures, including occupational, home and hobbies, are highly prevalent across ILD subtypes, including IPF, connective tissue disease-associated ILD (CTD-ILD) and unclassifiable ILD. Data from two distinct cohorts identified potentially relevant exposures, including avocational and para-occupational exposures, in 65% and 62% of all ILD cases, with higher exposure prevalence in men compared to women, although the contribution of inhalation exposure to disease development or progression could not be established conclusively in all cases [60–65].

Silica exposure is an established risk factor for autoimmune conditions including systemic sclerosis [63–65] but little is known about its relationship with other CTD-associated ILD [66]. In a longitudinal familial pulmonary fibrosis cohort, development of interstitial lung abnormalities was independently associated with self-reported occupational or environmental exposures to aluminium smelting, lead, birds and mould [67]. Occupational rock dust in this cohort was further identified as a risk factor for radiologic honeycombing [68].

Diagnostic approach to patients with suspected occupational ILD

Initial assessment

The possibility of an occupational aetiology should always be considered in the initial assessment of patients with ILD as occupational and idiopathic ILDs may be clinically indistinguishable, and 'occult' exogenous causes are easily missed unless an extensive occupational/environmental history is taken. Exposure history should include but is not limited to, job role and details of what

activities are undertaken, an estimate of relevant exposures including duration and dose (where possible), latency and disease course. Questionnaires are commonly used in health surveillance programmes and may provide useful information about current or previous exposures. Standardized health questionnaires exist to identify respiratory symptoms suggestive of occupational disease [69, 70], but none is specific to ILD.

A multidisciplinary approach that includes pulmonologists, radiologists, pathologists, occupational medicine specialists and industrial hygienists, where available, should be pursued. Industrial hygienists and occupational physicians have a key role in preventing occupational ILD (and occupational lung diseases in general). As part of a team, these specialists are trained to recognize, evaluate and control environmental health hazards in the workplace. In this regard, the UK Health and Safety Executive's 'Dustbuster' is designed to assess compliance with workplace health regulations and the control measures in place to protect workers' health, with a focus on preventing occupational lung diseases, especially those caused by construction dust and other hazardous substances (<https://www.hse.gov.uk/lung-disease/help.htm>). Carlier et al. have recently reported that the integration of a specialized occupational consultation in the multidisciplinary evaluation of patients with ILD resulted in a change in diagnosis in 12.8% (18/141) of cases, with 15.6% of patients (22/141) being eligible to claim compensation for an occupational disease [71]. A diagnosis of occupational ILD carries legal consequences; indeed, once the occupational origin of the disease has been confirmed, patients can claim compensation. This is the case, for instance, of patients initially diagnosed with IPF who are eventually reclassified as asbestosis following multidisciplinary evaluation.

Tools for detecting occupational exposures

Several tools are available for exposure identification in patients with suspected or confirmed occupational ILD, but there is limited evidence guiding their application in clinical practice. A comprehensive patient history supplemented by validated relevant questionnaires to identify potential exposures is an essential part of the clinical assessment. Clinical improvement following antigen avoidance may inform about the causative exposure in HP. Environmental assessment by

occupational specialists and/or industrial hygienists may identify otherwise unrecognized exposures and antigens. Occupational environmental sampling may be informative, but these tools are not standardized. In HP, positive serum-specific immunoglobulin testing indicates exposure but does not prove causality, and negative test results do not exclude specific antigens as potential causes. Specific inhalational challenge and lymphocyte proliferation testing provide information on immunologic sensitization but do not establish causality. Overall, a multidisciplinary approach integrating clinical history, questionnaires, environmental assessment and sampling, and in selected cases, immunologic testing, provides the most comprehensive approach to exposure evaluation in patients with suspected occupational ILD [72, 73].

Clinical features

Occupational ILDs affect workers of both genders and all ethnicities, although they are more common in men due to historical working practices. The latency is variable; for many ILDs such as the pneumoconioses, it can be several years but for HP, CBD and hard metal disease, it can be much shorter. Similarly, acute and accelerated silicosis and ILD secondary to inhalation of fumes and toxic gases may have a short latency. Similar to idiopathic ILD, dyspnoea and cough are the most frequent presenting symptoms but wheezing and chest tightness may also occur. Patients with HP may present with chronological symptoms with onset after job or specific task initiation. Symptoms may progress over time and may demonstrate temporal variation with improvement on weekends, holidays, or when working in different areas. Lung auscultation is often normal and generally nonspecific but may reveal end-inspiratory squeaks in patients with bronchiolitis, inspiratory crackles in advanced stages of fibrosis or wheezing in large airways obstruction. Pulmonary function tests are an essential component in the initial assessment of patients with occupational ILD but are similarly nonspecific, as they may reveal a restrictive, obstructive or mixed ventilatory defect.

Diagnostic features

The diagnosis of occupational ILD is generally made based on a combination of compatible occupational exposure history and chest imaging, and the exclusion of other conditions that may mimic occupational ILD (Fig. 1). Despite its low sensitivity




Fig. 1 Diagnostic algorithm for occupational interstitial lung diseases.

for detecting early disease [74], chest radiograph remains a widely used imaging test for screening of occupational ILDs and for making a diagnosis, particularly in low-income countries. Chest CT has higher sensitivity for early disease and greater accuracy in defining disease pattern than chest radiograph (Table 2) and represents a pivotal tool in the diagnosis of occupational ILD [75].

The inhalation of inorganic particles may induce variable degrees of epithelial injury, and fibrogenic and hypersensitivity reactions, leading to pleomorphic and rarely specific CT abnormalities (Table 2). Radiographic features of asbestosis are nonspecific and may be indistinguishable from those of IPF (Fig. 2, Panels A,B); therefore, imaging should always be interpreted according to the

exposure history. Asbestosis also shares several histopathological features with IPF [76, 77] (Fig. 2, Panels C,D), with mineralogical studies supporting the concept of asbestosis-IPF misclassification by revealing high fibre burdens in the lung tissue of patients initially diagnosed with 'IPF' and revision of the diagnosis to 'asbestosis' [78]. The diagnosis of asbestosis requires the presence of interstitial fibrosis coupled with the identification of ≥ 2 asbestos bodies/ cm^2 counted on 5- μm thick iron-stained sections [79], which correspond to approximately 2000 asbestos bodies/g of dry lung. However, a confirmatory lung biopsy is rarely needed, and claims are generally made based on compatible clinical-radiological presentation and history of asbestos exposure [80–82]. Notably, marked differences exist in the propensity of

Table 2. Common radiological patterns observed in occupational interstitial lung disease (ILD).

Pattern of radiological presentation	Occupational diseases
Alveolar pattern	1. Acute silicosis 2. Indium-related ILD
Interstitial/variable degree of fibrosis	1. Asbestosis 2. Dust/chemical-related diffuse fibrosis
Nodular pattern	1. Nodular silicosis 2. Pulmonary massive fibrosis 3. Talcosis 4. Coal workers pneumoconiosis
Airways diseases	Large airways 1. Occupational asthma 2. Byssinosis Small airways/centrilobular 1. Early asbestosis 2. Siderosis 3. Hot-tub 4. Coal worker disease 5. Flavour workers disease 6. Nylon-flock workers disease 7. Giant cell interstitial pneumonia (hard metal disease)
Sarcoid-like reaction	1. Chronic beryllium disease 2. World Trade Center Lung

different asbestos fibre types to cause asbestosis, with commercial amphibole (amosite and crocidolite) being two or three orders of magnitude more potent than chrysotile. It is estimated that, compared to the levels of exposure required to cause pleural plaques, those required for asbestosis to occur are approximately 2.5-fold higher for chrysotile and 10-fold higher for amosite [79, 83].

A high level of exposure may cause alveolar proteinosis, which manifests as 'crazy paving' and ground glass opacities, as in acute silicosis (Fig. 3, Panels A,B), or Indium-induced ILD [84, 85].

Non-fibrotic HP may also manifest acutely following exposure to antigens to which the individual is sensitized and hyper-responsive [86]. Long-term, cumulative exposure may be associated with ground glass opacities, subpleural lines and traction bronchiectasis, sometimes with coexisting honeycombing, as in asbestosis or in dust-related diffuse fibrosis (Fig. 4, Panels A,B) [87]. Silica- or silicate-induced diseases can manifest with a nodular pattern, ranging from simple silicosis to PMF, depending on the size of nodules (below or above 1 cm, respectively) (Fig. 3, Panels C,D). Inhalation of ketone butter flavouring




Fig. 2 Panel a: Asbestosis. CT image showing peripheral reticulation and pleural thickening; centrilobular dots may be seen in early disease. Panel b: Asbestosis. Pleural plaques are frequently used to support a diagnosis of asbestosis (although pleural plaques are not asbestosis) given the nonspecific parenchymal findings. Panel c: Asbestosis. Fibrosis spreading in the interstitium around respiratory bronchioles (arrows), correlating with the radiologic finding of centrilobular dots in early asbestosis. Note asbestos body in the inset. Panel d: Asbestosis. Fibrosis spreads from bronchiole to bronchiole (asterisks) and can eventually be difficult to separate from the usual interstitial pneumonia (UIP) pattern of idiopathic pulmonary fibrosis (IPF), given the patchy distribution of the disease; however, asbestosis has less frequent honeycombing, involves the bronchioles and has only rare fibroblast foci.

diacetyl (as in food-flavouring workers, i.e. ‘popcorn worker’s lung’) [88] or sulphur mustard (gas) (as in the US military exposed during the Iran–Iraq War) [89] may result in constrictive bronchiolitis, which is characterized pathologically by subepithelial scarring leading to narrowing of the airway, and radiologically (i.e. CT) by mosaic attenuation/air trapping and centrilobular nodules [90]. Typically, constrictive bronchiolitis causes expiratory flow limitation. Similarly, nylon flock workers’ disease is characterized pathologically by lymphocytic bronchiolitis and, on CT, by patchy ground glass opacities, consolidation and diffuse centrilobular micronodules [91, 92].

Exposure to beryllium can cause BeS, which is diagnosed by the demonstration of a beryllium-induced immune response via the beryllium lymphocyte proliferation test (BeLPT) [93]. BeS is the

immunological precursor to CBD, with a rate of progression from BeS to CBD of 6%–8% per year after initial diagnosis [94]. As the BeLPT does not differentiate between CBD and BeS [95], a definite diagnosis of CBD requires evidence of non-caseating granulomatous inflammation in lung tissue (Fig. 5, Panels A–D).

Bronchoalveolar lavage (BAL) plays an important role in the diagnostic workup of patients with ILD, including occupational ILD, particularly when used in conjunction with clinical and CT data, thus reducing the need for more invasive procedures [96]. Electron microscopy (EM) can quantify mineral fibres and particles in BAL (as well as in lung tissue) and is also able to detect detailed elements via X-ray analytical EM [97]. In addition, with regard to the detection of asbestos fibres, EM using BAL has a similar sensitivity as light microscopy




Fig. 3 Panel a: Silicoproteinosis. HRCT image from a 51-year-old sandblaster showing extensive bilateral ground glass opacities and superimposed polygonal lines representing interlobular septal thickening (crazy paving pattern). Image courtesy Dr Nestor Muller. Panel b: Silicoproteinosis. Alveolar filling with eosinophilic proteinaceous material consisting of phospholipids or surfactant (asterisks). Mild interstitial thickening by inflammatory cell infiltration can also be seen (arrows). Panel c: Chronic simple silicosis. HRCT image from a 50-year-old man showing innumerable well-defined centrilobular nodules throughout the upper lobes. The nodules are most profuse in the posterior regions of the lungs, a common finding in silicosis. Image courtesy Dr Nestor Muller. Panel D: Chronic simple silicosis. Lung biopsy specimen from a contemporary US underground coal miner showing multiple silicotic nodules (arrows). Typically, the central part of the nodule is composed of concentric layers of collagen, whereas the peripheral zone is less organized and contains lymphocytes, dust-laden macrophages and loosely formed collagen. Note also the absence of visible black coal dust.

using lung tissue [98]. BAL in combination with transbronchial forceps biopsies can also be useful in the evaluation of exposure-related granulomatous lung disease such as CBD, sarcoidosis and non-fibrotic HP. Transbronchial lung cryobiopsy provides pathologists with larger samples of lung tissue compared to conventional forceps biopsies thus serving as an alternative to surgical lung biopsy in certain scenarios [99]. When diagnostic uncertainty persists, surgical lung biopsy may be required to confirm the diagnosis given the potential preventative, therapeutic, prognostic and legal implications of a diagnosis of occupational ILD. In such cases, a thorough review of the lung specimen by an expert pathologist looking for clues to exposures—of which the patient may not

be aware, or may have forgotten, given the long latency of some exposure-related disease—by light microscopy, polarized light microscopy or EM, as appropriate, is of outmost importance (Table 3).

Management

Management of occupational ILD is focused primarily on prevention, through controlling hazardous exposures in the workplace with adequate ventilation and personal protective equipment. Medical monitoring of exposed workers with effective screening programs is essential. Patients diagnosed with occupational ILD should be removed from further exposure, although whether this leads to any reduction in the rate of progression




Fig. 4 Panel a: Fibrotic hypersensitivity pneumonitis. A 59-year-old man with chronic occupational exposure to isocyanate compounds. High-resolution CT image shows extensive ground glass opacities, bilateral reticulation and areas of mosaic attenuation. Panel b: Fibrotic hypersensitivity pneumonitis. Surgical lung biopsy showing prominent centrilobular fibrosis (asterisks) with relative subpleural sparing. Inset: a small non-caseating granuloma.




Fig. 5 Chronic beryllium disease. A 70-year-old male, with a history of beryllium exposure due to hobby handicraft. CT scan shows an upper lobe-predominant micronodular pattern (Panels a), associated with areas of mosaic attenuation and lobular sparing in the lower lobes (Panel b). Transbronchial lung cryobiopsy revealed sarcoid-like granulomas in the alveolar interstitium (Panel c; arrows) and granulomas with a centrilobular distribution (Panel d; arrows). These findings are compatible with chronic beryllium disease.

Table 3. Distinguishing features of silicosis, chronic beryllium disease and sarcoidosis.

	Silicosis	Chronic beryllium disease	Sarcoidosis
Occupational exposure	Exposure to silica	Exposure to beryllium metal or metal oxide	Exposure to foreign antigens and inorganic particulates increases sarcoidosis risk
Clinical presentation	Dyspnoea, cough, chest pain, fatigue, weight loss	Dyspnoea, cough, fatigue, fever, weight loss	Multiple pulmonary and extrapulmonary manifestations
Radiological features	Centrilobular nodules, interlobular septal thickening, large consolidations, 'eggshell' calcifications of lymph nodes, architectural distortions, PMF	Upper lobe-predominant micronodules with a perilymphatic distribution, architectural distortion in fibrotic cases	Upper lobe-predominant perilymphatic micronodules, bilateral hilar and mediastinal lymphadenopathy, architectural distortion in fibrotic cases
Pathological features	Silicotic nodules	Noncaseating granulomas in the lung	Noncaseating granulomas in the lung, lymph nodes and/or other affected organs
Management	Primarily avoidance of exposure	Primarily avoidance of exposure	Steroid/immunomodulatory treatment when required

Abbreviation: PMF, progressive massive fibrosis.

of the disease is not definitely known. Health-care professionals should have an informed and balanced discussion with the patient about the risks to their health of continuing exposure versus the socio-economic impact of changing their job or ceasing work. All workers should be advised to refrain from cigarette smoking given its potential pathogenic synergy. Additional cornerstones of disease management include treatment of comorbidities, pulmonary rehabilitation, supportive care (e.g. supplemental oxygen) and, in advanced or rapidly progressive cases, lung transplantation [100]. Appropriate advice about compensation schemes and legal aspects, which will vary between countries, should also be pursued. Systemic glucocorticoids are the first-line treatment for sarcoidosis [101] and may be efficacious in HP and CBD but are rarely used for other pneumoconioses. Tumour necrosis factor- α antagonists (i.e. infliximab or adalimumab) may be indicated in sarcoidosis patients with persistently active/progressive disease despite immunosuppressive therapy [102]. Bronchodilators and inhaled glucocorticoids may be used in the presence of coexisting airway disease. The utility of immunosuppressive medications (e.g. mycophenolate mofetil) is unproven, although they may be considered on a case-by-case basis for patients with the suggestion of active inflammation [103]. Whole lung-lavage may be efficacious in acute silicoproteinosis unresponsive to

broad-spectrum antibiotics and steroid treatment [104].

Nintedanib is approved for the treatment of non-IPF fibrotic ILDs that progress despite standard management [105] based on data from a randomized placebo-controlled trial in 663 patients with progressive fibrosing ILD, including 39 patients with 'exposure-related ILDs' (21 randomized to nintedanib and 18 randomized to placebo) [106]. Subgroup analysis by ILD diagnosis showed that nintedanib reduces significantly the annual rate of decline in forced vital capacity in patients with exposure-related ILDs, with a difference of 252.8 mL/year (95% CI 79.2, 426.5) compared to placebo [107]. Conversely, the role of pirfenidone in the treatment of patients with occupational progressive pneumoconiosis remains to be elucidated [108, 109].

Co-morbidities

The risk for tuberculosis is up to 20-fold higher in silica-exposed individuals compared to those not exposed [110]. This combination (often referred to as silico-tuberculosis) may be refractory to standard therapy, thus requiring specific expertise to guide prolonged multi-drug treatment. Silica exposure might further increase the risk for lung cancer [111] and is associated with CTDs [112]. Asbestos exposure is associated with a high

incidence of lung cancer and pleural mesothelioma [113], with mesothelioma also potentially originating from peritoneal serosal membranes [114], as well as colon and laryngeal cancer [114]. Given the risk of ILD exacerbation or progression due to infection, appropriate immunization and aggressive treatment of respiratory infections are recommended [75]. CWP might be associated with an increased occurrence of immune-mediated diseases such as rheumatoid arthritis (Caplan syndrome) [75, 115]. Other general principles of ILD management apply also to patients with occupational ILD (e.g. pulmonary rehabilitation, oxygen and lung transplantation) [116].

Economic burden of occupational ILDs

The economic burden of occupational ILDs in terms of disability, workers' compensation, health expenditures and lost revenue is difficult to estimate, and very few studies have addressed the problem. This is particularly true for occupational ILDs caused by novel/non-conventional exposures. Moreover, physicians unfamiliar with occupational lung disease may fail to elicit a thorough exposure history, thus missing valuable data. Accordingly, the data that do exist (e.g. disability statistics, death certificates and hospitalization admission diagnoses) may not be accurate or complete [117], and the true burden of exposure-related lung disease is likely to be significantly underestimated. In 2004, in the United States only, estimates of cost for occupational diseases, including respiratory illnesses, exceed \$26 billion annually, but the true economic burden is likely to be much higher [118].

Disease prevention

The greatest risk factor for occupational ILD is repeated respiratory exposure to a hazardous agent, indicating the importance and potential benefit of preventative strategies. Disease prevention requires a comprehensive strategy, including environmental monitoring of workplace hazards (often undertaken by occupational or industrial hygienists), health surveillance, education of employers and workforce, implementation of behavioural changes and workplace practices, research and regulation. Most high- and medium-income countries have legal frameworks and agencies that control occupational health and safety, setting standards for workplace/occupational exposure limits. These limits define the level below which no major health risks are expected to occur.

The hierarchy of controls is a widely used system to facilitate primary prevention of disease by eliminating or minimizing exposure to hazards in the workplace [119]. The most effective strategy is complete removal of the hazard. Where this is not possible or reasonably achievable, a stepwise approach is used to reduce exposures by substituting less hazardous materials, using engineering controls (e.g. local exhaust ventilation) and adopting different practices. Use of appropriate respiratory protection, while often the easiest (and least expensive) option, is generally ineffective and should be used only as a last resort. Where there is a residual risk of disease, workers should be enrolled in a respiratory health surveillance program. This is a form of secondary prevention, which aims to detect disease early, frequently prior to onset of symptoms, to allow an implementation of interventions and prevent further disease progression. Such programs involve periodic assessment of the workforce using a variety of tools depending on the industry and relevant exposures. Most commonly, spirometry, generally in conjunction with a questionnaire about respiratory symptoms, is used. This is of most value when spirometric indices are plotted longitudinally; specialist software is available to aid an identification of accelerated decline [120]. In surveillance of silica- and coal-exposed workers, chest X-rays (in conjunction with spirometry, questionnaires and—in some countries—clinical examination) are used. Although high-resolution CT is more sensitive for detection of disease, this must be balanced by the cost, radiation exposure and high detection of incidental findings compared with chest X-rays. In the United States, medical surveillance for beryllium-exposed workers also includes immunological testing for sensitization using BeLPT. Finally, the risk is greater for those working in countries or industries where health and safety are poorly regulated and for temporary workers who may not have the same access to surveillance programs.

Perspectives and closing remarks

Millions of workers are exposed to substances known to cause occupational ILD worldwide, particularly in low-middle-income countries and low SDI regions wherein occupational safety standards may be lacking or suboptimal. In addition, the number of reported associations between novel exposures and ILD continues to grow due to the introduction of new materials and changes in manufacturing practices (Table 4). Data on disease

Table 4. Interstitial lung diseases due to emerging agents or new settings for established agents.

Exposure	Interstitial lung disease
Denim sandblasting	Silicosis
Inhaled nanoparticles (polyacrylate)	Interstitial pneumonia
Organic chemicals	
Isocyanates	Hypersensitivity pneumonitis
Polyhexamethylene guanidine phosphate (PHMG) and oligo (2-(2-ethoxy) ethoxyethyl guanidinium chloride (PGH) compounds	Interstitial pneumonia; pulmonary fibrosis
5-chloro-2-methyl-4-isothiazolin-3-one (CMIT) and 2-methyl-4-isothiazolone-3-one (MIT)	Interstitial pneumonia
Cross-linked acrylic acid-based polymer (L-PAA)	Interstitial pneumonia; pulmonary fibrosis
Military deployment (desert dust particulate matter, burn pit emission products, vehicular diesel exhaust, jet fuel exhaust, oil well fires, debris from detonation, industrial fires, exposures to chemicals, fumes, gases and dusts)	Bronchiolitis obliterans; acute eosinophilic pneumonia; granulomatous pneumonitis; rapidly progressive pulmonary fibrosis
Flavouring materials (diacetyl (2,3-butanedione) and acetylpropionyl (2,3-pentanedione))	Bronchiolitis obliterans
Nylon flock	Nonspecific interstitial pneumonia/fibrosis with bronchiolocentric lymphoid nodules and lymphocytic bronchiolitis; diffuse alveolar damage; organizing pneumonia
Indium tin oxide	Interstitial pneumonia, pulmonary alveolar proteinosis
Man-made disasters (World Trade Center-related lung disease)	Sarcoidosis; interstitial pneumonia; pulmonary fibrosis
Welder's lung (welding fumes from electrode, filler wire and fluxes; base metal, shielding gases; paint or surface coating; metal oxides)	Respiratory bronchiolitis (with risk of progression to desquamative interstitial pneumonia with ongoing exposure)

incidence and prevalence remains scarce, whether this is due to under-recognition of occupational causes, under-reporting or both, highlighting the need for more national ILD registries to be collecting country-specific data on the ILD subtypes encountered and more specific training for health-care professionals about the importance of occupational exposures. Ideally, epidemiological studies reporting disease incidence or prevalence by number of workers exposed to a certain agent would allow comparisons between regions, countries, offending agent and type of exposure. A standard nomenclature is also encouraged within these registries with different occupational diseases and their country-specific frequency clearly listed. The emergence of novel potential occupational causes of ILD in recent years emphasizes the need for continuing vigilance.

Author contributions

Conception of the article; literature search and writing of the manuscript: Paolo Spagnolo, Christopher J. Ryerson, Kerri A. Johannson, Vincent Cottin. *Literature search and writing of the manuscript:* Sabina Guler, Johanna Feary, Andrew P. Fontenot, Zarir Udwadia, Wim A. Wuyts. *Provision of the histological images and writing of the manuscript:* Andrew Churg. *Provision of the radiological images and writing of the manuscript:* Sara Piciucchi. *Writing of the manuscript:* Tamera J. Corte. All authors approved the final version.

Conflict of interest statement

PS reports grants, personal fees and non-financial support from PPM Services and Boehringer Ingelheim; grants from Hoffmann-La Roche; personal

fees from Chiesi, Novartis, Galapagos, Lupin, Pieris, CSL Behring, AstraZeneca, GlycoCore Pharma and Menarini outside the submitted work; wife employee of Astra Zeneca. CJR reports grants and personal fees from Boehringer Ingelheim and Hoffmann-La Roche; personal fees from Astra Zeneca, Veracyte, Ensho, Pliant Therapeutics and Cipla outside the submitted work.

SG reports personal fees from Boehringer Ingelheim and Hoffmann-La Roche outside the submitted work. AC reports personal fees from various US law firms in asbestos litigation outside the submitted work. TC reports grants and personal fees from Boehringer Ingelheim and Roche; grants from Biogen and Galapagos; personal fees from BMS, DevPro and Vicore outside the submitted work. WAW reports grants and personal fees from Boehringer Ingelheim; grants from Galapagos and Roche outside the submitted work.

KAJ reports grants and personal fees from Three Lakes Foundation; grants from Chest Foundation, University of Calgary CSM and University Hospital Foundation; personal fees from Boehringer Ingelheim, Hoffmann-La Roche, Pliant Therapeutics and Thryon outside the submitted work. VC reports grants, personal fees and non-financial support from Boehringer Ingelheim; personal fees from Astra Zeneca, Celgene/BMS, CSL Behring, Ferrer/United Therapeutics, Fibrogen, Galapagos, Galecto, GSK, Pliant, Pure Tech, RedX, Roche, Sanofi and Shionogi, outside the submitted work.

The other authors declare no conflicts of interest.

References

- 1 Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med*. 2013;**188**:733–48.
- 2 Blanc PD, Annesi-Maesano I, Balmes JR, Cummings KJ, Fishwick D, Miedinger D, et al. The occupational burden of nonmalignant respiratory diseases. An official American thoracic society and European respiratory society statement. *Am J Respir Crit Care Med*. 2019;**199**:1312–34.
- 3 Occupational Interstitial Lung Disease. <https://www.dir.ca.gov/dwc/DWCPropRegs/2020/MTUS-Evidence-Based-Updates-June-2020/Occupational-Interstitial-Lung-Disease.pdf>
- 4 Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. *Am J Respir Crit Care Med*. 1994;**150**:967–72.
- 5 McDonald JC. Incidence by occupation and industry of acute work related respiratory diseases in the UK, 1992–2001. *Occup Environ Med*. 2005;**62**:836–42.
- 6 Barber CM, Wiggins RE, Carder M, Agius R. Epidemiology of occupational hypersensitivity pneumonitis; reports from the SWORD scheme in the UK from 1996 to 2015. *Occup Environ Med*. 2017;**74**:528–30.
- 7 Fenclová Z, Pelclová D, Urban P, Navrátil T, Klusáčková P, Lebedová J. Occupational hypersensitivity pneumonitis reported to the Czech national registry of occupational diseases in the period 1992–2005. *Ind Health*. 2009;**47**:443–8.
- 8 Rosenman KD, Reilly MJ, Henneberger PK. Estimating the total number of newly-recognized silicosis cases in the United States. *Am J Ind Med*. 2003;**44**:141–7.
- 9 Carder M, Darnton A, Gittins M, Stocks SJ, Ross D, Barber CM, et al. Chest physician-reported, work-related, long-latency respiratory disease in Great Britain. *Eur Respir J*. 2017;**50**:1700961.
- 10 Shi P, Xing X, Xi S, Jing H, Yuan J, Fu Z, et al. Trends in global, regional and national incidence of pneumoconiosis caused by different aetiologies: an analysis from the Global Burden of Disease Study 2017. *Occup Environ Med*. 2020;**77**:407–14.
- 11 Li J, Yin P, Wang H, Wang L, You J, Liu J, et al. The burden of pneumoconiosis in China: an analysis from the Global Burden of Disease Study 2019. *BMC Public Health*. 2022;**22**:1114.
- 12 Wang D, Liang R, Yang M, Ma J, Li W, Mu M, et al. Incidence and disease burden of coal workers' pneumoconiosis worldwide, 1990–2019: evidence from the Global Burden of Disease Study 2019. *Eur Respir J*. 2021;**58**:2101669.
- 13 Tjoe Nij E. Radiographic abnormalities among construction workers exposed to quartz containing dust. *Occup Environ Med*. 2003;**60**:410–7.
- 14 Akgun M, Araz O, Akkurt I, Eroglu A, Alper F, Saglam L, et al. An epidemic of silicosis among former denim sandblasters. *Eur Respir J*. 2008;**32**:1295–303.
- 15 Nandi SS, Dhatrak SV, Sarkar K. Silicosis, progressive massive fibrosis and silico-tuberculosis among workers with occupational exposure to silica dusts in sandstone mines of Rajasthan state: an urgent need for initiating national silicosis control programme in India. *J Family Med Prim Care*. 2021;**10**:686–91.
- 16 <https://www.cdc.gov/niosh/topics/surveillance/ords/nationalstatistics.html>
- 17 Goswami E, Craven V, Dahlstrom D, Alexander D, Mowat F. Domestic asbestos exposure: a review of epidemiologic and exposure data. *Int J Environ Res Public Health*. 2013;**10**:5629–70.
- 18 Moore I, Wrobel J, Rhodes J, Lin Q, Webster S, Jo H, et al. Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database. *BMC Pulm Med*. 2020;**20**:257.
- 19 Jindal SK. Silicosis in India: past and present. *Curr Opin Pulm Med*. 2013;**19**:163–8.
- 20 Kaul B, Cottin V, Collard HR, Valenzuela C. Variability in global prevalence of interstitial lung disease. *Front Med (Lausanne)*. 2021;**8**:751181.
- 21 Dos S Antao VC. Rapidly progressive coal workers' pneumoconiosis in the United States: geographic clustering and other factors. *Occup Environ Med*. 2005;**62**:670–4.

- 22 Leso V, Fontana L, Romano R, Gervetti P, Iavicoli I. Artificial stone associated silicosis: a systematic review. *Int J Environ Res Public Health*. 2019;**16**:568.
- 23 Pérez-Alonso A, Córdoba-Doña JA, Millares-Lorenzo JL, Figueroa-Murillo E, García-Vadillo C, Romero-Morillo J. Outbreak of silicosis in Spanish quartz conglomerate workers. *Int J Occup Environ Health*. 2014;**20**:26–32.
- 24 Hoy RF, Baird T, Hammerschlag G, Hart D, Johnson AR, King P, et al. Artificial stone-associated silicosis: a rapidly emerging occupational lung disease. *Occup Environ Med*. 2018;**75**:3–5.
- 25 Kramer MR, Blanc PD, Fireman E, Amital A, Guber A, Rhahman NA, et al. Artificial stone silicosis [corrected]: disease resurgence among artificial stone workers. *Chest*. 2012;**142**:419–24.
- 26 León-Jiménez A, Hidalgo-Molina A, Conde-Sánchez MÁ, Pérez-Alonso A, Morales-Morales JM, García-Gámez EM, et al. Artificial stone silicosis: rapid progression following exposure cessation. *Chest*. 2020;**158**:1060–8.
- 27 Cooper JH, Johnson DL, Phillips ML. Respirable silica dust suppression during artificial stone countertop cutting. *Ann Occup Hyg*. 2015;**59**:122–6.
- 28 Cohen RA, Petsonk EL, Rose C, Young B, Regier M, Najmuddin A, et al. Lung pathology in U.S. coal workers with rapidly progressive pneumoconiosis implicates silica and silicates. *Am J Respir Crit Care Med*. 2016;**193**:673–80.
- 29 GBD 2016 Occupational Chronic Respiratory Risk Factors Collaborators. Global and regional burden of chronic respiratory disease in 2016 arising from non-infectious airborne occupational exposures: a systematic analysis for the Global Burden of Disease Study 2016. *Occup Environ Med*. 2020;**77**:142–50.
- 30 Chen S, Liu M, Xie F. Global and national burden and trends of mortality and disability-adjusted life years for silicosis, from 1990 to 2019: results from the global burden of disease study 2019. *BMC Pulm Med*. 2022;**22**:240.
- 31 Mckee AS, Atif SM, Falta MT, Fontenot AP. Innate and adaptive immunity in noninfectious granulomatous lung disease. *J Immunol*. 2022;**208**:1835–43.
- 32 Fontenot A, Maier L. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease. *Trends Immunol*. 2005;**26**:543–9.
- 33 Mccanlies EC. HLA-DPB1 and chronic beryllium disease: a HuGE review. *Am J Epidemiol*. 2003;**157**:388–98.
- 34 Henneberger PK, Goe SK, Miller WE, Doney B, Groce DW. Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed. *J Occup Environ Hyg*. 2004;**1**:648–59.
- 35 Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. *N Engl J Med*. 1989;**320**:1103–9.
- 36 Saltini C, Kirby M, Trapnell BC, Tamura N, Crystal RG. Biased accumulation of T lymphocytes with “memory”-type CD45 leukocyte common antigen gene expression on the epithelial surface of the human lung. *J Exp Med*. 1990;**171**:1123–40.
- 37 Fontenot AP, Canavera SJ, Gharavi L, Newman LS, Kotzin BL. Target organ localization of memory CD4(+) T cells in patients with chronic beryllium disease. *J Clin Invest*. 2002;**110**:1473–82.
- 38 Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. *Science*. 1993;**262**:242–4.
- 39 Richeldi L, Kreiss K, Mroz MM, Zhen B, Tartoni P, Saltini C. Interaction of genetic and exposure factors in the prevalence of berylliosis. *Am J Ind Med*. 1997;**32**:337–40.
- 40 Potolicchio I, Mosconi G, Forni A, Nemery B, Seghizzi P, Sorrentino R. Susceptibility to hard metal lung disease is strongly associated with the presence of glutamate 69 in HLA-DP beta chain. *Eur J Immunol*. 1997;**27**:2741–3.
- 41 Terho EO, Heinonen OP, Lammi S. Incidence of farmer's lung leading to hospitalization and its relation to meteorological observations in Finland. *Acta Med Scand*. 1983;**213**:295–8.
- 42 Depierre A, Dalphin JC, Pernet D, Dubiez A, Faucompre C, Breton JL. Epidemiological study of farmer's lung in five districts of the French Doubs province. *Thorax*. 1988;**43**:429–35.
- 43 Grant IWB, Blyth W, Wardrop VE, Gordon RM, Pearson JCG, Mair A. Prevalence of farmer's lung in Scotland: a pilot survey. *BMJ*. 1972;**1**:530–4.
- 44 Barnes H, Troy L, Lee CT, Sperling A, Strek M, Glaspole I. Hypersensitivity pneumonitis: current concepts in pathogenesis, diagnosis, and treatment. *Allergy*. 2022;**77**:442–53.
- 45 Sanderson W, Kullman G, Sastre J, Olenchock S, O'campo A, Musgrave K, et al. Outbreak of hypersensitivity pneumonitis among mushroom farm workers. *Am J Ind Med*. 1992;**22**:859–72.
- 46 Woodard ED. Outbreak of hypersensitivity pneumonitis in an industrial setting. *JAMA*. 1988;**259**:1965–9.
- 47 Cummings KJ, Stanton ML, Nett RJ, Segal LN, Kreiss K, Abraham JL, et al. Severe lung disease characterized by lymphocytic bronchiolitis, alveolar ductitis, and emphysema (BADE) in industrial machine-manufacturing workers. *Am J Ind Med*. 2019;**62**:927–37.
- 48 Fernández Pérez ER, Kong AM, Raimundo K, Koelsch TL, Kulkarni R, Cole AL. Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. *Ann Am Thorac Soc*. 2018;**15**:460–9.
- 49 Quirce S, Vandenplas O, Campo P, Cruz MJ, De Blay F, Koschel D, et al. Occupational hypersensitivity pneumonitis: an EAACI position paper. *Allergy*. 2016;**71**:765–79.
- 50 Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet P-Y, Müller-Quernheim J. Sarcoidosis. *Lancet*. 2014;**383**:1155–67.
- 51 Oliver LC, Zarnke AM. Sarcoidosis: an occupational disease? *Chest*. 2021;**160**:1360–7.
- 52 Newman KL, Newman LS. Occupational causes of sarcoidosis. *Curr Opin Allergy Clin Immunol*. 2012;**12**:145–50.
- 53 Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, et al. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. *Am J Respir Crit Care Med*. 2004;**170**:1324–30.
- 54 Barnard J, Rose C, Newman L, Canner M, Martyny J, Mccammon C, et al. Job and industry classifications associated with sarcoidosis in a case-control etiologic study of Sarcoidosis (ACCESS). *J Occup Environ Med*. 2005;**47**:226–34.
- 55 Izbicki G, Chavko R, Banauch GI, Weiden MD, Berger KI, Aldrich TK, et al. World Trade Center “sarcoid-like”

- granulomatous pulmonary disease in New York City Fire Department rescue workers. *Chest*. 2007;**131**:1414–23.
- 56 Beijer E, Meek B, Bossuyt X, Peters S, Vermeulen RCH, Kromhout H, et al. Immunoreactivity to metal and silica associates with sarcoidosis in Dutch patients. *Respir Res*. 2020;**21**:141.
 - 57 Park Y, Ahn C, Kim T-H. Occupational and environmental risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analyses. *Sci Rep*. 2021;**11**:4318.
 - 58 Abramson MJ, Murambadoro T, Alif SM, Benke GP, Dharmage SC, Glaspole I, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study. *Thorax*. 2020;**75**:864–9.
 - 59 Paolucci G, Folletti I, Torén K, Ekström M, Dell'omo M, Muzi G, et al. Occupational risk factors for idiopathic pulmonary fibrosis in Southern Europe: a case-control study. *BMC Pulm Med*. 2018;**18**:75.
 - 60 Lee CT, Adegunsoye A, Chung JH, Ventura IB, Jablonski R, Montner S, et al. Characteristics and prevalence of domestic and occupational inhalational exposures across interstitial lung diseases. *Chest*. 2021;**160**:209–18.
 - 61 Lee CT, Strek ME, Adegunsoye A, Wong AW, Assayag D, Cox G, et al. Inhalational exposures in patients with fibrotic interstitial lung disease: presentation, pulmonary function and survival in the Canadian Registry for Pulmonary Fibrosis. *Respirology*. 2022;**27**:635–44.
 - 62 Lee CT, Feary J, Johannson KA. Environmental and occupational exposures in interstitial lung disease. *Curr Opin Pulm Med*. 2022;**28**:414–20.
 - 63 Shtraichman O, Blanc PD, Ollech JE, Fridel L, Fuks L, Fireman E, et al. Outbreak of autoimmune disease in silicosis linked to artificial stone. *Occup Med (Lond)*. 2015;**65**:444–50.
 - 64 Freire M, Alonso M, Rivera A, Sousa A, Soto A, Gómez-Sousa JM, et al. Clinical peculiarities of patients with scleroderma exposed to silica: a systematic review of the literature. *Semin Arthritis Rheum*. 2015;**45**:294–300.
 - 65 Sack CS, Doney BC, Podolanczuk AJ, Hooper LG, Seixas NS, Hoffman EA, et al. Occupational exposures and subclinical interstitial lung disease. The MESA (multi-ethnic study of atherosclerosis) air and lung studies. *Am J Respir Crit Care Med*. 2017;**196**:1031–9.
 - 66 Blanco-Pérez JJ, Arnalich-Montiel V, Salgado-Barreira Á, Alvarez-Moure MA, Caldera-Díaz AC, Melero-Gonzalez R, et al. Prevalence and clinical impact of systemic autoimmune rheumatic disease in patients with silicosis. *Arch Bronconeumol*. 2021;**57**:571–6.
 - 67 Salisbury ML, Hewlett JC, Ding G, Markin CR, Douglas K, Mason W, et al. Development and progression of radiologic abnormalities in individuals at risk for familial interstitial lung disease. *Am J Respir Crit Care Med*. 2020;**201**:1230–9.
 - 68 Copeland CR, Donnelly EF, Mehrad M, Ding G, Markin CR, Douglas K, et al. The association between exposures and disease characteristics in familial pulmonary fibrosis. *Ann Am Thorac Soc*. 2022;**19**:2003–12.
 - 69 Minette A. Questionnaire of the European Community for Coal and Steel (ECSC) on respiratory symptoms. 1987–updating of the 1962 and 1967 questionnaires for studying chronic bronchitis and emphysema. *Eur Respir J*. 1989;**2**:165–77.
 - 70 Jones PW, Quirk FH, Baveystock CM. The St George's respiratory questionnaire. *Respir Med*. 1991;**85**(Suppl B):25–31.
 - 71 Carlier S, Nasser M, Fort E, Lamouroux C, Si-Mohamed S, Chalabreysse L, et al. Role of the occupational disease consultant in the multidisciplinary discussion of interstitial lung diseases. *Respir Res*. 2022;**23**:332.
 - 72 Barnes H, Glaspole I. Occupational interstitial lung diseases. *Immunol Allergy Clin North Am*. 2023;**43**:323–39.
 - 73 Johannson KA, Barnes H, Bellanger A-P, Dalphin J-C, Fernández Pérez ER, Flaherty KR, et al. Exposure assessment tools for hypersensitivity pneumonitis. An Official American Thoracic Society Workshop Report. *Ann Am Thorac Soc*. 2020;**17**:1501–9.
 - 74 Hoffman TW, Van Es HW, Biesma DH, Grutters JC. Potential interstitial lung abnormalities on chest X-rays prior to symptoms of idiopathic pulmonary fibrosis. *BMC Pulm Med*. 2022;**22**:329.
 - 75 Litow FK, Lee Petsonk E, Bohnker BK, Brodtkin CA, Cowl CT, Guidotti TL, et al. Occupational interstitial lung diseases. *J Occup Environ Med*. 2015;**57**:1250–4.
 - 76 Corrin B, Dewar A, Rodriguez-Roisin R, Turner-Warwick M. Fine structural changes in cryptogenic fibrosing alveolitis and asbestosis. *J Pathol*. 1985;**147**:107–19.
 - 77 Copley SJ, Wells AU, Sivakumaran P, Rubens MB, Gary Lee YC, Desai SR, et al. Asbestosis and idiopathic pulmonary fibrosis: comparison of thin-section CT features. *Radiology*. 2003;**229**:731–6.
 - 78 Monsó E, Tura J, Pujadas J, Morell F, Ruiz J, Morera J. Lung dust content in idiopathic pulmonary fibrosis: a study with scanning electron microscopy and energy dispersive x ray analysis. *Br J Ind Med*. 1991;**48**:327–31.
 - 79 Roggli VL, Gibbs AR, Attanoos R, Churg A, Popper H, Cagle P, et al. Pathology of asbestosis—an update of the diagnostic criteria: report of the asbestosis committee of the college of American pathologists and pulmonary pathology society. *Arch Pathol Lab Med*. 2010;**134**:462–80.
 - 80 Churg A, Vedral S. Fiber burden and patterns of asbestos-related disease in workers with heavy mixed amosite and chrysotile exposure. *Am J Respir Crit Care Med*. 1994;**150**:663–9.
 - 81 Churg A. Asbestos-related disease in the workplace and the environment: controversial issues. *Monogr Pathol*. 1993;**36**:54–77.
 - 82 Gaensler EA, Jederlinic PJ, Churg A. Idiopathic pulmonary fibrosis in asbestos-exposed workers. *Am Rev Respir Dis*. 1991;**144**:689–96.
 - 83 Churg A, Wright JL, Vedral S. Fiber burden and patterns of asbestos-related disease in chrysotile miners and millers. *Am Rev Respir Dis*. 1993;**148**:25–31.
 - 84 Cummings KJ, Donat WE, Etensohn DB, Roggli VL, Ingram P, Kreiss K. Pulmonary alveolar proteinosis in workers at an indium processing facility. *Am J Respir Crit Care Med*. 2010;**181**:458–64.
 - 85 Marchiori E, Souza CA, Barbassa TG, Escuissato DL, Gasparetto EL, Souza AS. Silicoproteinosis: high-resolution CT findings in 13 patients. *AJR Am J Roentgenol*. 2007;**189**:1402–6.
 - 86 Spagnolo P, Rossi G, Cavazza A, Bonifazi M, Paladini I, Bonella F, et al. Hypersensitivity pneumonitis: a comprehensive review. *Investig Allergol Clin Immunol*. 2015;**25**:237–50.
 - 87 Laney AS, Weissman DN. Respiratory diseases caused by coal mine dust. *J Occup Environ Med*. 2014;**56**(Suppl), S18–22.

- 88 Akpınar-Elci M, Travis WD, Lynch DA, Kreiss K. Bronchiolitis obliterans syndrome in popcorn production plant workers. *Eur Respir J*. 2004;**24**:298–302.
- 89 Ghanei M, Tazelaar HD, Chilosi M, Harandi AA, Peyman M, Akbari HMH, et al. An international collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients. *Respir Med*. 2008;**102**:825–30.
- 90 Cox CW, Rose CS, Lynch DA. State of the art: imaging of occupational lung disease. *Radiology*. 2014;**270**:681–96.
- 91 Kern DG 3rd. Flock worker's lung: chronic interstitial lung disease in the nylon flocking industry. *Ann Intern Med*. 1998;**129**:261–72.
- 92 Weiland DA, Lynch DA, Jensen SP, Newell JD, Miller DE, Crausman RS, et al. Thin-section CT findings in flock worker's lung, a work-related interstitial lung disease. *Radiology*. 2003;**227**:222–31.
- 93 Hines SE, Pacheco K, Maier LA. The role of lymphocyte proliferation tests in assessing occupational sensitization and disease. *Curr Opin Allergy Clin Immunol*. 2012;**12**:102–10.
- 94 Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. *Am J Respir Crit Care Med*. 2005;**171**:54–60.
- 95 Balmes JR, Abraham JL, Dweik RA, Fireman E, Fontenot AP, Maier LA, et al. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease. *Am J Respir Crit Care Med*. 2014;**190**:e34–59.
- 96 Meyer KC, Raghu G. Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? *Eur Respir J*. 2011;**38**:761–9.
- 97 De Vuyst P, Karjalainen A, Dumortier P, Pairon J, Monso E, Brochard P, et al. Guidelines for mineral fibre analyses in biological samples: report of the ERS working group. *Eur Respir J*. 1998;**11**:1416–26.
- 98 Kido T, Morimoto Y, Yatera K, Ishimoto H, Ogoshi T, Oda K, et al. The utility of electron microscopy in detecting asbestos fibers and particles in BALF in diffuse lung diseases. *BMC Pulm Med*. 2017;**17**:71.
- 99 Troy LK, Grainge C, Corte TJ, Williamson JP, Vallely MP, Cooper WA, et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. *Lancet Respir Med*. 2020;**8**:171–81.
- 100 <https://www.dir.ca.gov/dwc/DWCPropRegs/2020/MTUS-Evidence-Based-Updates-June-2020/Occupational-Interstitial-Lung-Disease.pdf>
- 101 Spagnolo P, Rossi G, Trisolini R, Sverzellati N, Baughman RP, Wells AU. Pulmonary sarcoidosis. Pulmonary sarcoidosis. *Lancet Respir Med*. 2018;**6**:389–402.
- 102 Baughman RP, Valeyre D, Korsten P, Mathioudakis AG, Wuyts WA, Wells A, et al. ERS clinical practice guidelines on treatment of sarcoidosis. *Eur Respir J*. 2021;**58**:2004079.
- 103 Ryerson CJ, Corte TJ, Myers JL, Walsh SLF, Guler SA. A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. *Eur Respir J*. 2021;**58**:2100276.
- 104 Stafford M, Cappa A, Weyant M, Lara A, Ellis J, Weitzel NS, et al. Treatment of acute silicoproteinosis by whole-lung lavage. *Semin Cardiothorac Vasc Anesth*. 2013;**17**:152–9.
- 105 Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med*. 2022;**205**:e18–47.
- 106 Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. *N Engl J Med*. 2019;**381**:1718–27.
- 107 Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respir Med*. 2020;**8**:453–60.
- 108 Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med*. 2020;**8**:147–57.
- 109 Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. *Lancet Respir Med*. 2021;**9**:476–86.
- 110 Rimal B, Greenberg AK, Rom WN. Basic pathogenetic mechanisms in silicosis: current understanding. *Curr Opin Pulm Med*. 2005;**11**:169–73.
- 111 Sato T, Shimosato T, Klinman DM. Silicosis and lung cancer: current perspectives. *Lung Cancer (Auckl)*. 2018;**9**:91–101.
- 112 Rubio-Rivas M, Moreno R, Corbella X. Occupational and environmental scleroderma. Systematic review and meta-analysis. *Clin Rheumatol*. 2017;**36**:569–82.
- 113 Amin W, Linkov F, Landsittel DP, Silverstein JC, Becich MJ. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. *F1000Research*. 2018;**7**:1184.
- 114 Straif K, Benbrahim-Tallaa L, Baan R, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens—Part C: Metals, arsenic, dusts, and fibres. *Lancet Oncol*. 2009;**10**:453–4.
- 115 Caplan A, Payne RB, Withey JL. A broader concept of Caplan's syndrome related to rheumatoid factors. *Thorax*. 1962;**17**:205–12.
- 116 Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. *N Engl J Med*. 2020;**383**:958–68.
- 117 Schulte PA. Characterizing the burden of occupational injury and disease. *J Occup Environ Med*. 2005;**47**:607–22.
- 118 Goldyn S, Condos R, Rom W. The burden of exposure-related diffuse lung disease. *Semin Respir Crit Care Med*. 2008;**29**:591–602.
- 119 <https://www.cdc.gov/niosh/topics/hierarchy/default.html>
- 120 <https://www.cdc.gov/niosh/topics/spirometry/spirola-software.html>

Correspondence: Paolo Spagnolo, Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, via Giustiniani 2, 35128 Padova, Italy.
Email: paolo.spagnolo@unipd.it